IRVINE, Calif., Jan. 18, 2023 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the highly anticipated national launch of JUVÉDERM ® VOLUX™ XC. The long-lasting ...
IRVINE, Calif., Feb. 8, 2022 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announces the FDA approval of JUVÉDERM ® VOLBELLA ® XC for improvement of infraorbital hollows in ...
JUVÉDERM® VOLUX™ XC IS THE FIRST AND ONLY HYALURONIC ACID (HA) FILLER TO RECEIVE U.S. FDA APPROVAL FOR IMPROVING JAWLINE DEFINITION IRVINE, Calif., Aug. 3, 2022 /PRNewswire/ -- Today, Allergan ...
Perioral Rhytids Allergan announced that the Food and Drug Administration (FDA) has approved Juvederm Volbella XC for use in lip augmentation and for correction of perioral rhytids (referred to as ...
IRVINE, Calif.--(BUSINESS WIRE)--Allergan, Inc., (NYSE:AGN) today announced that the company has received approval from the U.S. Food and Drug Administration (FDA) to market JUVÉDERM VOLUMA™ XC, the ...
"The number one facial concern patients have is the eye area,12 so it is essential to consider treating the temples as part of a comprehensive treatment plan. With the approval and training-led launch ...
The FDA has approved Juvéderm XC (hyaluronic acid and lidocaine [preservative-free] injectable gel, from Allergan) dermal filler for injection into the mid-to-deep dermis for correction of moderate to ...
The FDA has approved marketing of Juvéderm Volbella XC for lip augmentation and correcting perioral rhytids in adults, according to a press release from Allergan. Juvéderm Volbella XC (hyaluronic acid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback